

**SUGGESTED FORMULA****Morphine Sulfate Pentahydrate 0.2mg/mL and Lidocaine Gel (Swish/Swallow) Suspension**

Version number: 1.0

Volume: 100 mL

Morphine Sulfate Pentahydrate (M1167)	0.02gm
Purified Water, USP	10mL
Lidocaine Viscous 2% Gel	10mL
Vehicle for Oral Suspension, NF (Ora-Plus™)	40mL
Vehicle for Oral Solution, NF (Ora-Sweet™)	Q.S. 100mL

\* Formulations for Vehicle for Oral Suspension, Oral Solution and Lidocaine Viscous 2% Gel can be found at [SpectrumRx.com>Services>Formulations](https://www.spectrumrx.com/Services/Formulations)

**SUGGESTED COMPOUNDING PROCEDURES**

1. Calculate the required quantity of each ingredient for the total amount to be prepared
2. Accurately weigh and/or measure each ingredient
3. Dissolve the Morphine Sulfate Pentahydrate in the Purified Water
4. Add the Lidocaine Viscous Suspension to the Morphine Sulfate Solution mixing well
5. Add the Vehicle for Oral Suspension to the Morphine Sulfate Solution mixing well
6. Add sufficient Vehicle for Oral Solution to bring the Volume to 100mL and mix well
7. Package and Label
8. Suggested Quality Assessments – follow pharmacy SOPs:
  - a. Weight to Volume calculation
  - b. Pourability
  - c. Settling/Resuspendability
  - d. Label - auxiliary labels, storage, BUD, compounded medication

Recommended auxiliary labels should include:

- Do not drink alcoholic beverages with this medicine
- May cause drowsiness
- For Oral use only
- Keep out of the reach of children
- Shake well and Refrigerate

Store in air tight amber plastic containers refrigerated

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

**Beyond-Use Date should be assigned based on the current volume of USP <795>**

Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment. Use safety enclosures (hoods) when weighing and mixing.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein.

9/18 JD